Business ❯ Biotechnology

Pharmaceuticals

Drug Development Acquisitions Clinical Trials Vaccine Development Cancer Treatment Immunotherapy Oncology Manufacturing Gene Therapy Biosimilars

Clearmind’s AUD Candidate Meets Early Safety Goal as Shares Double

The non-hallucinogenic MEAI pill advanced past the dose-escalation safety gate.

Definium Therapeutics Jumps to 52-Week High After Trump Order on Psychedelic Treatments

Investor Lawsuits Build After FDA Rebukes ImmunityBio Over Anktiva Promotion

Hemmati Emerges as Front-Runner to Lead FDA’s Vaccine and Biologics Center

FDA Issues Second Rejection of Replimune’s RP1 Melanoma Therapy

Evotec Leans Into Biologics as Horizon Overhaul Sets 2026 Reset

Gilead to Acquire Tubulis for Up to $5 Billion to Boost Cancer ADC Pipeline

Securities Class Action Filed Against ImmunityBio After FDA Flags Anktiva Marketing

ImmunityBio Faces Growing Securities Suits After FDA Flags Misleading Anktiva Claims

SCYNEXIS Acquires Poxel’s PXL-770 for ADPKD, Plans 2026 Phase 2 Trial

Novartis to Acquire Excellergy in Up to $2 Billion Deal for Next-Gen Anti-IgE

PTAB Reaffirms Broad Institute’s Priority for CRISPR-Cas9 in Eukaryotic Cells

FDA Approves First Glucocorticoid Receptor Blocker for Platinum-Resistant Ovarian Cancer

Gilead to Buy Ouro Medicines for $1.675 Billion Upfront to Advance Autoimmune T‑Cell Engager

Oncomatryx Raises €58 Million With Public Backing to Pursue Gipuzkoa Manufacturing Plant

AIM ImmunoTech Secures Final Japan Patent for Ampligen Checkpoint-Inhibitor Cancer Therapy

Codexis Posts Q4 Beat on Merck Deal, Sets 2026 Outlook

BioNTech Founders to Exit by 2026 and Launch New mRNA Startup as Shares Slide

BioNTech Founders to Exit This Year to Launch New mRNA Company as Stock Slumps on Weak Outlook

Lilly, Samsung Biologics to Open First Gateway Labs Outside U.S. and China in Songdo by July 2027